Optymalizacja programowania wszczepialnych kardiowerterówdefibrylatorów dla zmniejszenia liczby wyładowań

• Authors: Zbigniew Szafraniec , Jerzy Krzysztof Wranicz

Title variants

EN

Implantable cardioverter-defibrillators programming optimization to reduce the number of shocks

• Languages of publication: PL

Abstracts

PL

Wynalezienie wszczepialnych kardiowerterów-defibrylatorów (ang. Implantable Cardioverter-Defibrillators – ICD) wyznacza nową epokę w dziejach zapobiegania nagłemu zgonowi sercowemu. W pewnych sytuacjach klinicznych, takich jak np. zespół Brugadów czy wrodzony zespół wydłuŜonego QT, wszczepienie ICD jest jedynym skutecznym sposobem zabezpieczenia chorych przed groźnymi dla Ŝycia napadowymi częstoskurczami komorowymi oraz migotaniem komór. Niestety kaŜda terapia niesie ze sobą potencjalne zagroŜenia, którymi w przypadku ICD jest problem obciąŜenia pacjentów nieadekwatnymi wyładowaniami oraz wpływ tych wyładowań na jakość Ŝycia, a nawet jego długość. Dostępne współcześnie ICD oferują wiele parametrów programowalnych, które odpowiednio ustawione mogą zminimalizować wspomniane zagroŜenia. W artykule omówiono zagadnienie optymalizacji programowania ICD w celu zmniejszenia liczby wyładowań.

EN

The invention of implantable cardioverter-defibrillators (ICDs) marked out a new era in the management of sudden cardiac death. In some cases, like Brugada syndrome or long QT syndrome, ICD is the only effective treatment of serious paroxysmal ventricular tachycardias or ventricular fibrillation. Unfortunately every treatment comes at a price of possible complications, and ICDs are not an exception, inappropriate shocks and their influence on life quality or even life duration, to name just few. Contemporary devices offer plenty programmable functions which, when suitably used, may minimize the risk of the issues mentioned above. Below we discuss some of the recently popular ICD optimization algorithms, that could reduce pernicious adverse effects of this crucial therapy.

Keywords

EN

automatic cardioverter-defibrillator; automatyczny kardiowerter-defibrylator; nagły zgon sercowy; optimization; optymalizacja; programming; programowanie; sudden cardiac death

Discipline

• MEDICINE: MEDICINE

• Publisher: Łódzkie Towarzystwo Naukowe
• Journal: Folia Medica Lodziensia
• Year: 2010
• Volume: 37
• Issue: 2
• Pages: 243-258

Contributors

author

Zbigniew Szafraniec

• Zakład Elektrokardiologii I Katedry Kardiologii i Kardiochirurgii, Uniwersytet Medyczny w Łodzi

author

Jerzy Krzysztof Wranicz

• Zakład Elektrokardiologii I Katedry Kardiologii i Kardiochirurgii, Uniwersytet Medyczny w Łodzi

References

• Mirowski M, Mower MM, Staewen WS, Tabatznik B, Mendeloff AI. Standby automatic defibrillator. An approach to prevention of sudden coronary death. Arch Intern Med. 1970; 126:158-161.
• Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P i wsp. MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008; 51:1357-1365.
• Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R i wsp. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352:225-237.
• Runsiö M, Kallner A, Källner G, Rosenqvist M, Bergfeldt L. Myocardial injury after electrical therapy for cardiac arrhythmias assessed by troponin-T release. Am J Cardiol. 1997; 79:1241-1245.
• Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF i wsp. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation. 2005; 111:2898-2905.
• Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM. EMPIRIC Trial Investigators. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol. 2006; 48:330-339.
• Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW i wsp. PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008; 52:541-550.
• Kühlkamp V, Dörnberger V, Mewis C, Suchalla R, Bosch RF, Seipel L. Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J Cardiovasc Electrophysiol. 1999; 10:905 915.
• Friedman PA, McClelland RL, Bamlet WR, Acosta H, Kessler D, Munger TM I wsp. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation. 2006; 113:2871-2879.
• Almendral J, Arribas F, Wolpert C, Ricci R, Adragao P, Cobo E i wsp. DATAS Writing Committee; DATAS Investigators. Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial. Europace. 2008; 10:528-535.
• Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R i wsp. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004; 351:2481-2488.
• Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D i wsp. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009; 361:1427-1436.
• Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29:2388-2442.
• Lim HS, Lip GY, Tse HF. Implantable cardioverter defibrillator following acute myocardial infarction: the '48-hour' and '40-day' rule. Europace. 2008; 10:536-539.
• Goldberg R, Szklo M, Tonascia JA, Kennedy HL. Acute myocardial infarction. Prognosis complicated by ventricular fibrillation or cardiac arrest. JAMA. 1979; 241: 2024-2027.
• Jensen GV, Torp-Pedersen C, Hildebrandt P, Kober L, Nielsen FE, Melchior T i wsp. Does in-hospital ventricular fibrillation affect prognosis after myocardial infarction? Eur Heart J. 1997; 18:919-924.
• Gasparini M, Menozzi C, Proclemer A, Landolina M, Iacopino S, Carboni A i wsp. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study. Eur Heart J. 2009; 30:2758-2767.
• Sweeney MO, Sherfesee L, DeGroot PJ, Wathen MS, Wilkoff BL. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010; 7:353-360.
• Badanie w trakcie – patrz: http://clinicaltrials.gov/ct2/show/NCT00947310? term=madit-rit&rank=1
• Badanie w trakcie – patrz: http://clinicaltrials.gov/ct2/show/NCT00743522? term=provide&rank=3

• Document Type: paper